Related Experiment Video
Updated: Apr 7, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
CCR 20th Anniversary Commentary: Chimeric Antigen Receptors-From Model T to the Tesla
1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. phwu@mdanderson.org.
Abstract:
The research article by Kershaw and colleagues, published in the October 15, 2006, issue of Clinical Cancer Research, presents one of the first clinical trials to utilize chimeric antigen receptors. Subsequent studies have shown promise for the treatment of patients with lymphoid malignancies, but further progress will require optimization, including the identification of more specific antigens for solid tumors.
Insights
Chimeric antigen receptor (CAR) therapy shows promise for lymphoid malignancies. Further research is needed to identify specific antigens for solid tumors to advance CAR T-cell treatments.
Area of Science:
- Immunotherapy
- Oncology
- Molecular Biology
Background:
- The study explores chimeric antigen receptor (CAR) therapy, a novel approach in cancer treatment.
- It references the early clinical trial by Kershaw and colleagues in 2006, a foundational work in the field.
Observation:
- The article highlights the initial clinical application of CARs in cancer research.
- It notes the subsequent promise shown by CAR therapy for lymphoid malignancies.
Findings:
- Early clinical trials utilizing CARs were investigated.
- The potential of CAR therapy for treating lymphoid cancers was observed.
Implications:
- Optimization of CAR therapy is crucial for future progress.
- Identifying specific antigens is essential for expanding CAR applications to solid tumors.
